The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
Open accessAbstract
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two Phase II trials have investigated the effects of saroglitazar, a PPARα/γ agonist, and found improvement of ALT and hepatic fat (measured via MRI‐PDFF) [57] but no improvement of NAS (primary endpoint: delta change of NAS from baseline to Week 24 biopsy) [58].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Saroglitazar, a dual PPAR a / c agonist has been shown to improve insulin resistance, liver steatosis and liver enzymes 426 and is approved in India for the treatment of T2D and MASH.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [426]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This lack of basic information may have confounded true treatment effects and results in serious difficulties concerning cross-trial comparisons [240].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [240]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citation2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationVernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 379
Unagolla, J. M., Das, S., Flanagan, R., Oehler, M., & Menon, J. U. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124381 · Cited by 31
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 33
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31
Koh, B., Xiao, J., Ng, C. H., Law, M., Gunalan, S. Z., Danpanichkul, P., Ramadoss, V., Sim, B., Tan, E. Y., Teo, C. B., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001028 · Cited by 31
Self-citationHu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 34
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 33
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 36
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 30
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients
Padole, P., Arora, A., Sharma, P., Chand, P., Verma, N., & Kumar, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.015 · Cited by 29
Ziamanesh, F., Mohammadi, M., Ebrahimpour, S., Tabatabaei‐Malazy, O., Mosallanejad, A., & Larijani, B. A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01293-3 · Cited by 28
Rohm, T. V., Reis, F. C. G., Rocha, K. C. E., Isaac, R., Strayer, S., Murphy, C., Bandyopadhyay, G. K., Gao, H., Ganguly, S., Nguyen, T. T. B., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.033 · Cited by 30
Zhou, Z., Jin, R., Gu, Y., Ji, Y., Lou, Y., & Wu, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s524893 · Cited by 29
Bae, J. C., Beste, L. A., & Utzschneider, K. M. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1434 · Cited by 27
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 26
Emerging targets for therapy in ALD: Lessons from NASH
Singal, A. K., Shah, V. H., & Malhi, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000381 · Cited by 26
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
Heinle, J. W., DiJoseph, K., Sabag, A., Oh, S., Kimball, S. R., Keating, S., & Stine, J. G. (2023) · Nutrients · doi:10.3390/nu15112452 · Cited by 26
Jin, H., Feng, X., Feng, S., Dai, L., Zhu, W., & Yuan, Z. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155188 · Cited by 25
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 28
Drug‐Induced Liver Injury in Patients With Chronic Liver Disease
Ghabril, M., Vuppalanchi, R., & Chalasani, N. (2025) · Liver International · doi:10.1111/liv.70019 · Cited by 28
Self-citationAt the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 35
Linghu, L., Zong, W., Liao, Y., Chen, Q., Meng, F., Wang, G., Liao, Z., Lan, X., & Chen, M. (2023) · Research · doi:10.34133/research.0276 · Cited by 25
Current strategies for nonalcoholic fatty liver disease treatment (Review)
Sun, J., Jin, X., & Li, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5412 · Cited by 27
Nicchio, I. G., Cirelli, T., Quil, L. C. D. C., Camilli, Â. C., Scarel‐Caminaga, R. M., & Leite, F. R. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116908 · Cited by 28
Emerging pharmacological treatment options for MAFLD
Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 59
Mao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 25
Prasoppokakorn, T., Pitisuttithum, P., & Treeprasertsuk, S. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00189 · Cited by 24
Miao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 25
Chen, J. Y. S., Chua, D., Lim, C. O., Ho, W. X., & Tan, N. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010158 · Cited by 24
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24
Review article: vascular effects of PPARs in the context of NASH
Guixé‐Muntet, S., Biquard, L., Szabó, G., Dufour, J., Tacke, F., Francque, S., Rautou, P., & Gracia‐Sancho, J. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17046 · Cited by 22
Wan, X., Ma, J., Bai, H., Hu, X., Ma, Y., Zhao, M., Liu, J., & Duan, J. (2025) · Biomolecules · doi:10.3390/biom15010140 · Cited by 25
Hu, X., Fan, J., Ma, Q., Han, L., Cao, Z., Xu, C., Luan, J., Jing, G., Nan, Y., Wu, T., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01456-z · Cited by 22
Kakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 24
Perazza, F., Leoni, L., Selvatici, B., Girolami, F., Bonalumi, A., Beretta, A., Ferri, S., Petroni, M. L., Piscaglia, F., Ravaioli, F., et al. (2025) · Nutrients · doi:10.3390/nu17111906 · Cited by 25
Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., & Gao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1639064 · Cited by 24
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 21
Macrophage fatty acid oxidation in atherosclerosis
Xiao, S., Qi, M., Zhou, Q., Gong, H.-Q., Wei, D., Wang, G., Feng, Q., Wang, Z., Liu, Z., Zhou, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116092 · Cited by 25
Zargar, A. H., Bhansali, A. K., Majumder, A., Maheshwari, A., Bhattacharyya, A., Dasgupta, A., Saboo, B., Sethi, B. K., Sanyal, D., Seshadri, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16496 · Cited by 25
Siddiqui, M. S., Parmar, D., Shaikh, F., Forsgren, M. F., Patel, S. S., Bui, A. T., Boyett, S. L., Patel, V. A., & Sanyal, A. J. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000110 · Cited by 20
Self-citationCui, T., Xiao, X., Pan, Z., Tang, K., Zhong, Y., Chen, Y., Guo, J., Duan, S., Zhong, G., Li, T., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c04122 · Cited by 20
Hu, Y., Li, H., Zhang, H., Chen, X., Chen, J., Xu, Z., You, H., Dong, R., Peng, Y., Li, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42162-0 · Cited by 23
Branković, M., Dukić, M., Gmizić, T., Popadić, V., Nikolić, N., Sekulic, A. D., Brajković, M., Đokić, J., Mahmutović, E., Lasica, R., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020229 · Cited by 21
Targeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 20
Lu, Q., Zhang, L., Chen, Z., Lv, J., Gao, J., Li, X., Li, H., Shi, W. S., Li, X., Ma, H., et al. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110620 · Cited by 20
Li, Y., Ruiyu, W. U., Liu, R., Wu, K., Ding, M., Sun, R., Gu, Y., Zhou, F., Wu, J., Zheng, Q., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01089-4 · Cited by 19
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 22
Mandal, S. K., Puri, S., Kumar, B. K., Muzaffar-Ur-Rehman, M., Sharma, P. K., Murugesan, S., & Deepa, P. R. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10666-y · Cited by 19
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 22
Xie, L., Wang, H., Hu, J., Liu, Z., & Hu, F. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116104 · Cited by 19
Radu, F. I., Patoni, C., Nancoff, A.-S., Marin, F.-S., Gaman, L. E., Bucurica, A., Socol, C., Jinga, M., Duţu, M., & Bucurica, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084201 · Cited by 19
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Liver Steatosis: A Marker of Metabolic Risk in Children
Neri, C. R., Scapaticci, S., Chiarelli, F., & Giannini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094822 · Cited by 23
Hu, S., Ai, Y., Hu, C., Bawa, F. N. C., & Xu, Y. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101372 · Cited by 18
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 19
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 19
Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17
Lei, N., Song, H., Zeng, L., Ji, S., Meng, X., Zhu, X., Li, X., Feng, Q., Liu, J., & Mu, J. (2023) · Molecules · doi:10.3390/molecules28073185 · Cited by 20
Li, Z., Zheng, D., Zhang, T., Ruan, S., Li, N., Yang, Y., Yang, P., & Wang, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000343 · Cited by 20
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Khaznadar, F., Khaznadar, O., Petrovic, A., Hefer, M., Gjoni, F., Gjoni, S., Steiner, J., Smolić, M., & Bojanić, K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070376 · Cited by 20
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 17
Pi, D., Zheng, L., Pan, J., Zhen, J., Zheng, C., Fan, W. H., Song, Q., Pan, M., Yang, Q., & Zhang, Y. (2024) · Antioxidants · doi:10.3390/antiox13091026 · Cited by 16
Sun, Y., Wu, C., Xin, G., Zhong, B., Wu, X., Liu, Y., Shi, J., Zhang, Q., Zhao, Y., Gao, Y., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001475 · Cited by 17
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Bhopale, K. K., & Srinivasan, M. P. (2023) · Livers · doi:10.3390/livers3040040 · Cited by 17
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 16
Liu, Y., Wang, Y., Zhou, J., Li, H., Liu, C., Zhong, B., Liu, J., Liu, L., Zhang, L., & Sun, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1718799 · Cited by 15
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 16
Kumari, D., Gautam, J., Sharma, V., Gupta, S. K., Sarkar, S., Jana, P., Singhal, V., Babele, P., Kamboj, P., Bajpai, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22051 · Cited by 15
Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link
Vulchi, J., Suryadevara, V., Mohan, P., Kamalanathan, S., Sahoo, J., Naik, D., & Selvarajan, S. (2023) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00043 · Cited by 18
Trusz, G. J. (2024) · Differentiation · doi:10.1016/j.diff.2024.100793 · Cited by 15
PPARα activation partially drives NAFLD development in liver-specific Hnf4a-null mice
Kasano-Camones, C. I., Takizawa, M., Ohshima, N., Saito, C., Iwasaki, W., Nakagawa, Y., Fujitani, Y., Yoshida, R., Saito, Y., Izumi, T., et al. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad005 · Cited by 15
Grobbee, E. J., de Jong, V., Schrieks, I. C., Tushuizen, M. E., Holleboom, A. G., Tardif, J., Lincoff, A. M., Schwartz, G. G., Cabezas, M. C., & Grobbee, D. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277706 · Cited by 14
RetractedBasha, A., May, S. C., Anderson, R. M., Samala, N. R., & Mirmira, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129996 · Cited by 14
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 13
Recent updates on targeting the molecular mediators of NAFLD
Wang, J., Wang, L., Zhang, X., Zhang, P., Cai, J., She, Z., & Li, H. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02282-4 · Cited by 13
Grabowska, K., Buzdygan, W., Galanty, A., Wróbel‐Biedrawa, D., Sobolewska, D., & Podolak, I. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09864-1 · Cited by 16
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Colca, J. R., Tanis, S. P., Kletzien, R. F., & Finck, B. N. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263369 · Cited by 13
Update on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 13
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Gowda, D., Shekhar, C., Gowda, S. G. B., Chen, Y., & Hui, S. (2023) · Livers · doi:10.3390/livers3040045 · Cited by 15
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD
Iwaszko-Sochal, K., Kasztelan‐Szczerbińska, B., & Cichoż‐Lach, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176148 · Cited by 13
Long, C., Li, Z., Jiang, L., Yang, X., Deng, S., Jiang, Y., Zhang, B., & Yue, R. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02747-8 · Cited by 14
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 12
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 13
Chen, F., Liu, Q., Ma, L., Yan, C., Zhang, H., Zhou, Z., & Yi, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02803 · Cited by 12
Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
Che, W., Zhao, M., Li, X., Li, C., Cho, W. C. S., & Yu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002916 · Cited by 12
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 12
Zhang, Z., Yan, Q., Wu, W., Zhao, Y., Zhang, H., & Li, J. (2023) · Journal of International Medical Research · doi:10.1177/03000605231177191 · Cited by 12
Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025) · EngMedicine · doi:10.1016/j.engmed.2025.100088 · Cited by 11
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
NASH After Liver Transplantation: Impact of Immunosuppression
Taneja, S., Roy, A., & Duseja, A. K. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.03.013 · Cited by 11
Attia, S. H., Saadawy, S. F., El‐Mahroky, S. M., & Nageeb, M. M. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03004-y · Cited by 11
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Tan, Y., Hu, Y., Yang, Y., & Chu, H. (2025) · MedComm · doi:10.1002/mco2.70532 · Cited by 13
Pramanik, S., Pal, P., & Ray, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i2.91319 · Cited by 12
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 10
Vuppalanchi, R., Cruz, M. M., Momin, T., Shaikh, F., Swint, K., Patel, H., & Parmar, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3450 · Cited by 10
Self-citationLiu, C., Zheng, S., Wang, S., Wu, D., Jiang, W., Zeng, Q., Wei, Y., Zhang, Y., & Tang, H. (2022) · Diagnostics · doi:10.3390/diagnostics12061412 · Cited by 10
Metadata
- Authors
- Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N.
- Affiliations
- Indiana University School of Medicine (US)
- Cedars-Sinai Medical Center (US)
- Texas Liver Institute (US)
- Catalina Research Institute (US)
- Marion General Hospital (US)
- University of Florida Health (US)
- Liver Institute Northwest (US)
- Beth Israel Deaconess Medical Center (US)
- University of Miami (US)
- Zydus Discovery DMCC,Dubai,UAE
- Zydus Lifesciences Limited (India) (IN)
- Corresponding author
- Chalasani, Naga
- ORCID
- Venue
- Hepatology
- Published
- 2021-07-19
- Volume
- 74
- Issue
- 4
- Pages
- 1809-1824
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3149930516
- Cited by
- 379
- References
- 48
- Citations by year
- 2026: 46 · 2025: 82 · 2024: 82 · 2023: 87 · 2022: 57 · 2021: 25
- FWCI
- 45.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- Novo Nordisk
- Allergan
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- saroglitazar, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, PPAR alpha/gamma agonist, insulin resistance, atherogenic dyslipidemia, liver fat, ALT, adiponectin, triglycerides, drug safety and tolerability, weight gain, PPARγ antagonist, PPARα
- MeSH terms
- Adipose Tissue, Adult, Alanine Transaminase, Alkaline Phosphatase, Aspartate Aminotransferases, Cholesterol, Double-Blind Method, Female, gamma-Glutamyltransferase, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Phenylpropionates, Pyrroles, Triglycerides, Cholesterol, VLDL, PPAR alpha, PPAR gamma, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
